Market Overview:
Plasmid DNA (pDNA) have become important technology for modern healthcare sector. They are used as a therapeutic agent such as in gene therapy or generation of vaccine antigens or indirectly for various research applications.
The Global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 635.1 million in 2021 and is expected to exhibit a CAGR of 23.2% over the forecast period (2021-2028).
Get Free PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/2593
Key Drivers
Growing adoption of gene therapy is driving growth of the plasmid DNA manufacturing market. For instance, in October 2021, Terumo Blood and Cell Technologies (Terumo) and BioCentriq announce the formation of a strategic collaboration designed to accelerate the adoption of automated manufacturing to bring novel cell and gene therapies (CGT) to patients more quickly and cost effectively.
Increasing number of key players in the market is again augmenting plasmid DNA manufacturing market. For instance, in July 2021, Thermo Fisher Scientific Inc., has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
Covid-19 Impact Analysis
There was high demand for plasmid DNA during Covid-19 pandemic because plasmid are important nucleic acid-based vaccine and gene therapies that are used to produce Covid-19 vaccines. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 166 million infected individuals worldwide as of May 24, 2021.
Competitive Landscape:
Cobra Biologics and Pharmaceutical Services*, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Waisman Biomanufacturing, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., Cepham Life Sciences, Delphi Genetics, Biomiga, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd, Luina Bio Pty Ltd, Ajinomoto Bio-Pharma Services, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., and Geneone Life Science
Plasmid DNA Manufacturing Market Segmentation:
Global Plasmid DNA Manufacturing Market, By Product Type:
-
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno-Associated
- Others
- Plasmid DNA
- Non-viral
- Lipid/polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
Global Plasmid DNA Manufacturing Market, By Grade:
-
- GMP Grade
- R&D Grade
Global Plasmid DNA Manufacturing Market, By Application:
-
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
Global Plasmid DNA Manufacturing Market, By Development Phase:
-
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
By Region
Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America [United States, Canada, Mexico]
Middle East & Africa [GCC, North Africa, South Africa]
South America [Brazil, Argentina, Columbia, Chile, Peru].
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2593
Key Takeaways:
The plasmid DNA manufacturing market is expected to exhibit a CAGR of 23.2 % over the forecast period owing to the growing innovations in biopharmaceutical industry. For instance, in December 2018, LakePharma, Inc., a U.S. based biologics company, started operations of its new cGMP microBiomanufacturing Center for commercial manufacturing of plasmid DNA.
North America is expected to gain significant growth over the forecast period owing to the increasing focus of key players to expand production facility. For instance, in July 2021, Thermo Fisher Scientific has opened new facility in California for growing DNA therapy and RNA vaccine market. The facility – a 67,000-square-foot facility located at Thermo’s Carlsbad campus – will supply plasmid DNA for drug candidates in clinical trials as well as commercial supply.
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Grade
- Market Snapshot, By Application
- Market Snapshot, By Development Phase
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Outline of Plasmid DNA Production Process
- Key developments
- Regulatory Scenario
- Guidelines Specific for the Development of Plasmid DNA Vaccines
- Regulatory Pathway from Clinical Trials to Marketing Authorization
- Investment Opportunities
- PEST Analysis
- PORTER’S Five Analysis
- Pricing Analysis
- Technology Features, By Competitors
- Batch Size/Capacity
- Technology
- Technology Limitation
- Comparative Analysis of Different Types of Viral System
- Market Dynamics
- Global Plasmid DNA Manufacturing Market– COVID-19 Impact Analysis
- Pre-COVID Impact
- Post-COVID Impact
- Economic Impact
- Demand Supply Impact
- Global Plasmid DNA Manufacturing Market, By Product Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Viral Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retroviral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Adenoviral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Lentiviral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Adeno-Associated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Retroviral
- Plasmid DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Non-viral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Lipid/polymer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Electroporation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Nanoparticles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Grade, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- GMP Grade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- R&D Grade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Application, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Development Phase, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Pre-Clinical Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Clinical Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Marketed Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Geography, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North India
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 – 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
-
- Cobra Biologics and Pharmaceutical Services*
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- VGXI, Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aldevron
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Kaneka Corporation
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nature Technology Corporation
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PlasmidFactory GmbH & Co. KG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cell and Gene Therapy Catapult
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Waisman Biomanufacturing
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LakePharma, Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- MeiraGTx Limited
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eurofins Genomics
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vigene Biosciences
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Luminous BioSciences (LBS), LLC
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Genscript Biotech Corporation
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GENEWIZ
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Creative Biogene
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akron Biotech
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biomay
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- JAFRAL Ltd.,
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cepham Life Sciences
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Delphi Genetics
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biomiga
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GeneImmune Biotechnology Corp.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lonza
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Greenpak Biotech Ltd
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Luina Bio Pty Ltd
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ajinomoto Bio-Pharma Services
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Synbio Technologies
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Genopis Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Altogen Biosystems
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Puresyn, Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Geneone Life Science
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cobra Biologics and Pharmaceutical Services*
-
- Section
- Research Methodology
- About Us
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞!
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐭𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/2593
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837